Cytori Strengthens Global Intellectual Property Portfolio with Key Patents
November 16 2016 - 11:15AM
Business Wire
Cytori Therapeutics, Inc. (NASDAQ: CYTX) (“Cytori” or the
“Company”) announced today the issuance of a number of key patents
that strengthen its intellectual property portfolio in the U.S. and
Europe. Cytori now has over 90 global patents issued and another 55
patent applications pending around the globe. Several of Cytori’s
recently-issued patents contain claims providing protections for
Cytori’s program in the use of Cytori Cell Therapy™ for treating
scleroderma. Cytori recently completed enrollment in its STAR
approval trial in the US for this indication.
On November 1, 2016, US Patent No. 9480718 was issued. This
patent contains claims applying to the use of adipose derived cells
to treat peripheral vascular diseases (“PVD”), which are blood
circulation disorders that affect the blood carrying vessels of the
body that can narrow, experience spasm or become blocked. PVD is
often a contributory process in scleroderma. This patent has term
at least through 2022 and claims the use of Cytori Cell Therapy™
for PVD, including but not limited to PVD associated with
scleroderma.
On November 8, 2016, US Patent No. 9486484 was issued. This
patent provides protections around the use of adipose-derived cells
for the treatment of edema. Edema, also known as ‘swelling’, is
often accompanied by increased blood flow and is a very common
secondary clinical manifestation of numerous inflammatory and
immune-related conditions. Specifically, edema contributes directly
to the diminished hand dysfunction found often in the acute phases
of scleroderma. The ‘484 patent term lasts through at least
2029.
Other recently issued patents strengthen Cytori’s osteoarthritis
program. Last month, US Patent No. 9463203 was issued. The ‘203
patent protects the use of adipose-derived cells for treating
cartilage defects, including but not limited to osteoarthritic
defects, defects in the articular cartilage and defects in
meniscus. Earlier this year, Cytori completed the ACT-OA clinical
trial, a phase IIb trial assessing the use of adipose-derived cells
for the treatment of osteoarthritis of the knee. The ‘203 patent
term lasts through at least 2022.
The European Patent Office also recently issued European Patent
No. EP2617427 to Cytori. The ‘427 Patent protects the use of
adipose-derived cells for restoring tears in cartilage such as
those present in osteoarthritic joints, and has a patent term at
least through 2024.
On November 15, 2016 US Patent No. 9492483 was issued. The ‘483
Patent relates to the use of adipose-derived regenerative cells for
the treatment of burn, and area in which Cytori has had an active
research program for several years in conjunction with the US
Government. The ‘483 patent term lasts at least through December
2022.
“Cytori has amassed a large global intellectual property
position and continues to expand and strengthen the portfolio
through internal R&D efforts and targeted in-licensing,” noted
John D. Harris, Vice President and General Manager, Cell Therapy.
“The recent patents specifically serve to support our current
development efforts in scleroderma, osteoarthritis, and burn.”
About Cytori
Cytori Therapeutics is a late stage cell therapy company
developing autologous cell therapies from adipose tissue to treat a
variety of medical conditions. Data from preclinical studies and
clinical trials suggest that Cytori Cell Therapy™ acts principally
by improving blood flow, modulating the immune system, and
facilitating wound repair. As a result, Cytori Cell Therapy™ may
provide benefit across multiple disease states and can be made
available to the physician and patient at the point-of-care through
Cytori’s proprietary technologies and products. For more
information: visit www.cytori.com.
Cautionary Statement Regarding
Forward-Looking Statements
This press release includes forward-looking statements that
involve known and unknown risks and uncertainties. All statements,
other than historical facts are forward looking statements. Such
statements, including statements regarding projected patent terms,
and potential uses of Cytori’s patent portfolio to support its
product pipeline, are subject to risks and uncertainties that could
cause our actual results and financial position to differ
materially. Some of these risks include risks related to protection
and enforcement of our intellectual property portfolio such as
risks regarding infringing or competing third party intellectual
property, risks that our intellectual property may infringe other
intellectual property rights (or may be at risk of challenge or
invalidation), or risks that the claims in our patents and patent
applications may be insufficient in coverage or scope to support
and achieve our corporate objectives, and other risks and
uncertainties described under the "Risk Factors" in Cytori’s
Securities and Exchange Commission Filings, included in our annual
and quarterly reports.
There may be events in the future that we are unable to predict,
or over which we have no control, and our business, financial
condition, results of operations and prospects may change in the
future. We assume no responsibility to update or revise any
forward- looking statements to reflect events, trends or
circumstances after the date they are made unless we have an
obligation under U.S. Federal securities.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161116005525/en/
CYTORI THERAPEUTICSTiago Girao, +1
858-458-0900ir@cytori.com
Cytori Therapeutics (NASDAQ:CYTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cytori Therapeutics (NASDAQ:CYTX)
Historical Stock Chart
From Apr 2023 to Apr 2024